Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

CRBSI Treatment Market Outlook from (2023 to 2033)

The global catheter-related bloodstream infection (CRBSI) treatment market size was valued at US$ 1,466.9 million in 2022. It is expected to reach US$ 2,668.6 million by 2033. The catheter-related bloodstream infection (CRBSI) treatment market is slated to reach US$ 1,541.3 million by 2023.

The global catheter-related bloodstream infection (CRBSI) treatment market is anticipated to witness a considerable CAGR of 5.6% in the review period 2023 to 2033. The market for CRBSI in South Asia reached a valuation of US$ 469.9 million in 2022.

Latest Catheter-related Bloodstream Infection (CRBSI) Treatment Market Trends-

  • Combination therapies are expected to play a pivotal role in improving patient outcomes and enhancing the quality of care. Usage of different microbial agents with several mechanisms of action is a key trend in the Catheter-related bloodstream infection (CRBSI) treatment market.
  • As healthcare professionals strive to mitigate the risks associated with catheter use, a series of groundbreaking innovations is shaping the market and propelling it into a new era of infection prevention & patient safety.
  • Catheter-related bloodstream infections have long posed a challenge within healthcare settings, prompting a concerted effort to develop cutting-edge solutions. One prominent trend that is gaining momentum involves continuous advancements in catheter design and materials.
  • Modern innovations in catheters are meticulously engineered to significantly reduce infection risk. Among the most promising developments are antimicrobial coatings that coat the catheter’s surface.
  • Ability of antimicrobial coatings to actively prevent microbial colonization and biofilm formation is projected to propel their demand. These coatings release antimicrobial agents over time, creating a hostile environment for bacteria and fungi, thereby curbing the potential for infection transmission.
Attributes Key Insights
Catheter-related Bloodstream Infection (CRBSI) Treatment Market Estimated Size (2023E) US$ 1,541.3 million
Catheter-related Bloodstream Infection (CRBSI) Treatment Market Projected Valuation (2033F) US$ 2,668.6 million
Value-based Catheter-related Bloodstream Infection (CRBSI) Treatment Market CAGR (2023 to 2033) 5.6%
Collective Value Share: Top 5 Countries (2022) 59.4%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Key Catheter-related Bloodstream Infection (CRBSI) Treatment Market Highlights

Increasing CRBSI Prevalence Worldwide

The prevalence of catheter-related bloodstream infections (CRBSI) is a persistent and pressing concern across healthcare settings. This concern is particularly pronounced in healthcare facilities, where invasive procedures and the utilization of catheters are commonplace. As these infections continue to exert their impact, patients demand effective treatment solutions in this landscape.

The demand for treatments tailored to combat CRBSI is expected to surge in tandem with their prevalence. Innovations in medical technology are set to contribute to reducing the incidence of these infections.

Innovations in CRBSI Treatment

These innovations include ongoing advancements in catheter design, materials, and infection-resistant coatings. Research efforts to understand the underlying causes of CRBSI and develop novel treatment strategies are also underway, promising more targeted and potent interventions.

Infection Control and Transformative Focus

The intensifying focus on infection control across healthcare facilities and organizations is projected to ignite a transformative wave. It is expected to render patient safety and the mitigation of healthcare-associated infections (HAIs) as paramount objectives.

The emotional emphasis on infection prevention can also create a significant ripple effect that drives investments in catheter-related bloodstream infections (CRBSI) treatments. This is consequently anticipated to propel the CRBSI treatment demand.

Multifaceted Approach to Infection Control

The heightened focus on infection control is set to encompass a multifaceted approach. Rigorous adherence to hand hygiene protocols and meticulous environmental cleaning are expected to be integral to this strategy. This is also projected to include proper utilization and maintenance of medical devices, such as catheters.

Evidence-based guidelines and best practices are continuously evolving. It is further expected to compel healthcare organizations to embrace the latest advancements in infection prevention to bolster patient safety and care quality.

CRBSI Treatment Investments

Investments in CRBSI treatments are expected to be influenced by several factors. Institutions must demonstrate their commitment to patient safety as healthcare-associated infections garner public attention and scrutiny. To do so, they will likely adopt state-of-the-art solutions that can effectively combat CRBSI.

Financial implications of HAIs are substantial. It is projected to prompt healthcare administrators to invest in prevention strategies that can ultimately reduce costs associated with extended hospital stays and additional treatments. Rising focus on infection control in healthcare facilities is set to resonate as a powerful catalyst driving the catheter-related bloodstream infections (CRBSI) treatment market.

Research and Development Investments

Considerable research & development investments by pharmaceutical and medical device companies herald a new era in treating and preventing CRBSIs. These investments signify a collective determination to pioneer novel treatment modalities and innovative catheter technologies. These are expected to prioritize patient safety and elevate infection prevention strategies.

Commitment to a Bright Future

As the healthcare landscape evolves, the unwavering commitment to research & development underscores a shared aspiration to forge a bright future. This is expected to push the efficient management of CRBSIs, enhance patient outcomes, and expand healthcare innovations.

Catheter-related Bloodstream Infection (CRBSI) Treatment Market Hindrances

  • Evolution of Infectious Disease Management

Infectious diseases have historically been met with an evolving arsenal of therapeutic options. Antibiotics, antivirals, and antifungal medications have transformed the landscape of infectious disease management. However, the CRBSI treatment market paints a different picture.

  • Complexities of Catheter-related Infections

The inherent complexities of catheter-related infections are set to render the development of effective treatments. It can be intertwined with the use of medical devices that inadvertently facilitate pathogen entry.

  • Biofilm Formation and Protective Fortresses

The formation of biofilms on catheter surfaces is expected to further compound the challenge. These biofilms act as protective fortresses, harboring bacteria and impeding the penetration of antibiotics.

  • Limited Therapeutic Choices

The unique characteristics of CRBSI demand innovative approaches that can breach these protective barriers and target infections at their source. Yet, the limited options available are expected to hinder healthcare professionals' ability to choose therapies that effectively counteract biofilm-associated infections.

  • Limited Treatment Options

Limited treatment options available in the CRBSI treatment market are projected to impose a substantial restraint on the fight against catheter-related infections. This scarcity of therapeutic choices, compounded by biofilm complexities and antimicrobial resistance, can hamper the work of healthcare professionals as they endeavor to manage CRBSIS effectively.

  • Challenge of Antimicrobial Resistance

Antimicrobial resistance stands as a towering obstacle in the catheter-related bloodstream infection (CRBSI) treatment market. It will likely cast a shadow of urgency and complexity over efforts to effectively manage and combat these infections.

  • Impact of Antimicrobial Resistance

The escalating prevalence of antimicrobial-resistant bacteria has further morphed into a critical challenge, directly impacting the landscape of the CRBSI treatment market. This mounting resistance is projected to threaten to erode the efficacy of existing antibiotics. It is not only expected to diminish the range of available treatment options but also necessitate intricate maneuvers to develop novel therapies in the face of an evolving microbial adversary.

  • Two-fold Challenge of Antimicrobial Resistance

In the CRBSI treatment market, the challenge posed by antimicrobial resistance is two-fold. The effectiveness of established antibiotics, which have historically been the mainstay of infectious disease management, is compromised.

  • Daunting Shadow over the CRBSI Treatment Market

Pathogens that have developed resistance can continue to proliferate and thrive in the bloodstream. This can further lead to prolonged infections, increased morbidity, and elevated mortality rates among the affected patients. Increasing prevalence of antimicrobial-resistant bacteria is set to cast a daunting shadow over the CRBSI treatment market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

2018 to 2022 vs. 2023 to 2033 CRBSI Treatment Market Analysis

The global catheter-related bloodstream infection (CRBSI) treatment market exhibited a steady CAGR of around 4.2% during the historical period from 2018 to 2022. It stood at US$ 1,466.9 million in 2022. The market for Catheter-related bloodstream infection (CRBSI) treatment is anticipated to register a CAGR of 5.6% in the forecast period.

Historical Catheter-related Bloodstream Infection (CRBSI) Treatment Market Value (2022) US$ 1,466.9 million
Historical Value-based Catheter-related Bloodstream Infection (CRBSI) Treatment Market CAGR (2018 to 2022) 4.2%

Antimicrobial resistance is expected to pose a formidable threat to modern medicine. The indiscriminate use of antibiotics and other antimicrobial agents has significantly fueled this crisis from 2018 to 2022.

Acknowledging this critical concern, the approach to CRBSI treatment is evolving to balance the necessity of eradicating infections. This includes the imperative to preserve the efficacy of antimicrobials for future generations.

Adopting a holistic approach encompassing infection prevention and control measures alongside antimicrobial stewardship is vital. Stringent infection control protocols, proper catheter care, and reduced unnecessary catheter usage can lower the burden of CRBSIs. These factors are expected to minimize the need for extensive antimicrobial treatment.

The trend toward more judicious use of antimicrobial agents in CRBSI treatment is projected to reflect a pivotal moment in the fight against antimicrobial resistance. In the catheter-related bloodstream infection (CRBSI) treatment market, the utilization of antifungal agents is set to be a key component.

It is expected to be often governed by clinical guidelines in addressing the complex issue of hospital infections, particularly those associated with catheter use. The rising challenge of antibiotic resistance is projected to accentuate the need for innovative solutions. This is further anticipated to make developing and deploying practical clinical guidelines imperative.

In such a context, preventing and managing CRBSIs requires a multifaceted approach, including robust infection control measures and the judicious use of antibiotics & antifungal agents. These are all aimed at enhancing patient outcomes and reducing the burden of hospital-acquired infections.

Catheter-related bloodstream infection (CRBSI) represents a critical subset of healthcare-associated infections, often necessitating antibiotic treatment. These infections are set to be directly linked to the presence of catheters in medical settings. These are projected to emphasize the importance of infection prevention measures.

Innovations such as antimicrobial-coated catheters are expected to reduce the risk of bacterial and fungal infections. The pharmaceutical industry will likely play a pivotal role in developing antibiotics and antifungal agents essential for CRBSI treatment.

On the other hand, patient safety and infection prevention protocols remain paramount. These are anticipated to align with the broader goals of enhancing medical device safety and infectious disease management in the healthcare system.

Comparative Analysis of Adjacent CRBSI Treatment Markets

The global catheter-related bloodstream infection (CRBSI) treatment market is likely to be impacted by the peer or tangential markets in the healthcare sector. These include other markets, such as cervical dysplasia and pigmented lesion treatment. The global sales outlook of the catheter-related bloodstream infection (CRBSI) treatment market can provide deeper insights that can help develop unique differentiating strategies to pursue growth and opportunity.

Out of the three markets, the pigmented lesion treatment market is set to dominate, followed by the catheter-related bloodstream infection (CRBSI) treatment market, with valuations of US$ 3,591.3 million and US$ 1,541.3 million in 2023, respectively. All three markets are anticipated to expand with the surging demand for innovative medical treatment options that can help lower the healthcare burden and patient outcomes.

Catheter-related Bloodstream Infection (CRBSI) Treatment Market:

Attributes Catheter-related Bloodstream Infection (CRBSI) Treatment Market
CAGR (2023 to 2033) 5.6%
Market Value (2023) US$ 1,541.3 million
Growth Factor Rising adoption of catheters in healthcare institutions is expected to propel the cases of CRBSIs, thereby driving the need for effective treatment options.
Key Trend Emergence of infection-resistant technologies and new catheter designs is set to lower the risk of CRBSIs and help reduce the entry points for pathogens.

Cervical Dysplasia Treatment Market:

Attributes Cervical Dysplasia Treatment Market
CAGR (2023 to 2033) 3.0%
Market Value (2023) US$ 628.5 million
Growth Factor Growing awareness of cervical dysplasia and the ongoing expansion of several cervical cancer screening programs are set to support early diagnosis and treatment.
Key Trend Inclination toward minimally invasive surgeries is anticipated to initiate quicker recovery times and reduce discomfort.

Pigmented Lesion Treatment Market:

Attributes Pigmented Lesion Treatment Market
CAGR (2023 to 2033) 7.8%
Market Value (2023) US$ 3,591.3 million
Growth Factor Rising prevalence of skin cancer, such as melanoma will likely push the market as there is a surging need for effective treatment options for pigmented lesions.
Key Trend Integration of artificial intelligence (AI) in the assessment and diagnosis of pigmented lesions would enable healthcare professionals to accurately detect suspicious lesions and support early treatment.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insights

In the table below of the growth potential of the catheter-related bloodstream infection (CRBSI) treatment market, CAGRs of the top 5 countries are provided. Out of the 5, India is likely to lead the catheter-related bloodstream infection (CRBSI) treatment market by exhibiting a CAGR of 7.2% from 2023 to 2033. China and Indonesia are expected to witness catheter-related bloodstream infection (CRBSI) treatment demand at the same CAGR of 6.6%.

Catheter-related Bloodstream Infection (CRBSI) Treatment Market Growth Outlook by Key Countries

Country Value-based CAGR
United States 4.4%
India 7.2%
China 6.6%
Japan 5.7%
Indonesia 6.6%

Prevalence of HAIs in the United States Pushes CRBSI Antibiotic Therapy Demand

The United States catheter-related bloodstream infection market is anticipated to witness a 4.4% CAGR from 2023 to 2033. The country’s catheter-related bloodstream infection (CRBSI) treatment market size 2022 was US$ 233.9 million.

The United States has a significant incidence of CRBSIs due to the extensive use of catheters in healthcare settings. This high incidence is anticipated to drive the demand for CRBSI treatment drugs.

HAIs, including CRBSIs, have been a leading concern in the United States. Healthcare facilities and regulatory bodies have prioritized infection control. It is expected to lead to growing investments in prevention and treatment strategies.

As per the Centers for Disease Control and Prevention (CDC), healthcare in the United States is now safer than it was ten years ago due to the enormous advancements made toward the shared objective of eliminating HAIs. It is expected to be crucial to build on this achievement and keep working toward the eradication of HAIs.

CRBSI Industry Outlook in India to be pushed by Surging Healthcare Facilities

In the review period, India is expected to showcase a CAGR of around 7.2% in the catheter-related bloodstream infection (CRBSI) treatment market. The country is projected to reach a valuation of US$ 492.6 million by 2033.

India has one of the most prominent populations globally. This means a substantial patient pool can require CRBSI treatment. The sheer volume of patients is expected to drive demand for CRBSI-related products and services.

India also has a growing healthcare infrastructure, with an increasing number of hospitals, clinics, and healthcare facilities. This infrastructure is set to create new opportunities for the diagnosis and treatment of CRBSIs and the growth of infection control measures.

According to the India Brand Equity Foundation (IBEF), the healthcare sector in the country is anticipated to surge by three times, at a CAGR of 22% from 2016 to 2022, from US$ 110 billion to US$ 372 billion. The healthcare infrastructure in India is anticipated to cost US$ 349.1 billion by FY22.

CRBSI Treatment Antibiotics to Gain Impetus across China

China is estimated to record a steady CAGR of 6.6% in the review period. The country will likely reach US$ 422.8 million by 2033 in the catheter-related bloodstream infection (CRBSI) treatment market.

China has invested heavily in expanding its healthcare infrastructure by constructing new hospitals, clinics, and healthcare facilities. This expansion strategy is projected to help improve access to healthcare services, including CRBSI diagnosis and treatment.

China also has a rapidly growing pharmaceutical industry that produces many products, including antibiotics and antimicrobial agents used in CRBSI treatment. Pharmaceutical companies in the country are projected to invest in research & development activities through 2033.

The Shanghai Jiao Tong University School of Medicine conducted a study in June 2022 about the incidence rate and economic burden of CRBSI. The investigation was conducted in several ICUs across three tertiary-level hospitals connected to Shanghai Jiao Tong University, totaling 2300 beds. The Department of Infection Control regularly monitored for CRBSI in ten separate ICUs.

Hematology ICU had the most prominent incidence rate of CRBSI at 4.43 per 1000 CVC days. About 51 patients were matched correctly with controls. The annual expenditure in the CRBSI group was US$ 67,923, which was substantially more than that in the controlling group (P 0.001). CRBSI was responsible for the average cost of US$ 33,227.

Use of Micro Guide Catheters in Japan Fuels CRBSI Management Solutions Demand

Japan’s central line-associated bloodstream infection (CLABSI) treatment market is projected to record a CAGR of 5.7% from 2023 to 2033. It is anticipated to reach a valuation of US$ 230.1 million by 2033 in the catheter-related bloodstream infection (CRBSI) treatment market.

Rising demand for micro-guide catheters in Japan is anticipated to drive the catheter-related bloodstream infection (CRBSI) treatment market through 2033. Increasing use of these catheters in interventional cardiology, radiology, and other medical procedures is expected to aid demand.

Ongoing advancements in diagnostics and minimally invasive procedures are also projected to push the adoption of micro-guide catheters in Japan. With the rising use of these catheters, the prevalence of CRBSIs is also set to surge, thereby pushing the demand for effective treatment options.

Growing use of micro-guide catheters in intricate medical interventions is another vital factor projected to support growth in Japan. Underlying health conditions and compromised immune systems of patients undergoing these procedures can also propel them toward susceptibility to infections such as CRBSIs. This is expected to drive the demand for advanced CRBSI treatment options to ensure patient care and safety.

Infection Control Measures in Indonesia Spur CRBSI Therapy Market

Indonesia is expected to reach a valuation of US$ 135.4 million by 2033 in the intravascular catheter-related infection treatment industry. During the forecast period, it is estimated to witness a CAGR of 6.6% in the catheter-related bloodstream infection (CRBSI) treatment market.

Surging focus of healthcare professionals on infection control is expected to drive early detection and enhanced surveillance of CRBSIs in Indonesia. Several healthcare facilities are estimated to deploy cutting-edge monitoring systems to efficiently detect infections. Rising vigilance is expected to push the demand for CRBSI treatment options for managing complex cases once diagnosed.

Multiple healthcare companies in Indonesia are set to prioritize patient safety. CRBSIs are anticipated to be a crucial concern. Rising emphasis on patient safety and well-being is further set to push the need for CRBSI treatment options. This is attributed to the urgent need to ensure positive patient outcomes and lower infection risks.

Category-wise Insights

Echinocandin to be Mainly Used for Catheter-linked Infection Treatment

The table below highlights the global drug class growth of the catheter-related bloodstream infection market. Under drug class, the echinocandin segment will likely remain dominant in the assessment period.

The echinocandin segment, while smaller, is set to showcase a significant CAGR of 6.8% through 2033 in the catheter-related bloodstream infection (CRBSI) treatment market. It is expected to be followed by teicoplanin, vancomycin, daptomycin, cloxacillin, cefazoline, and ceftazidime segments.

Catheter-related Bloodstream Infection (CRBSI) Treatment Market Growth Outlook by Drug Class

Drug Class Value-based CAGR
Cloxacillin 5.8%
Ceftazidime 4.5%
Cefazoline 4.9%
Daptomycin 5.9%
Vancomycin 6.2%
Teicoplanin 6.3%
Echinocandin 6.8%
Others 4.7%

By drug class, the echinocandin segment will likely showcase a 6.8% CAGR in the forecast period in the catheter-related bloodstream infection (CRBSI) treatment market. As echinocandins are known for having antifungal solid effects when used with Candida species, they are expected to witness a surging demand globally. With the increasing development of the Candida species during CRBSIs, echinocandin is set to be ideal for combating fungal infections, especially those brought on by catheters.

Echinocandins are also expected to show a wide range of anti-Candida strain activity. It can include activities against those strains that have evolved sensitivity to different antifungal medications. Their versatility in targeting several fungal species is projected to raise their effectiveness in CRBSI scenarios when a particular microbial infection cannot be detected.

Echinocandins are also estimated to have a relatively low resistance rate compared to other antifungal classes. This feature is expected to help healthcare professionals use it to treat CRBSIs, where antimicrobial resistance can pose a significant challenge. Hence, their low risk of resistance development will likely contribute to their high demand.

End Users to Purchase CRBSI Control Solutions from Online Pharmacies

The table below highlights the global CRBSI treatment market demand analysis by distribution channel. Under the drug class, the online pharmacies segment will likely remain dominant in the assessment period.

The online pharmacies segment, while smaller, is set to showcase a significant CAGR of 6.6% through 2033 in the catheter-related bloodstream infection (CRBSI) treatment market. Hospital pharmacies, retail pharmacies, and drug store segments are expected to follow it.

Catheter-related Bloodstream Infection (CRBSI) Treatment Market Growth Outlook by Distribution Channel

Distribution Channel Value-based CAGR
Hospital Pharmacies 5.3%
Retail Pharmacies 5.6%
Drug Store 5.9%
Online Pharmacies 6.6%

In terms of distribution channels, the online pharmacies segment is projected to register a CAGR of 6.6% through 2033 in the catheter-related bloodstream infection (CRBSI) treatment market. Online pharmacies are expected to give customers the convenience of always being reachable. Without physically visiting pharmacies or medical institutions, healthcare professionals and patients can get choices, order, and browse for CRBSI treatment at their convenience.

A wider variety of CRBSI treatment options, including multiple brands and formulas, are set to be frequently offered by online pharmacies. These are anticipated to allow for investigation of other possibilities, evaluation of costs, and selection of the suitable course of action for their unique requirements.

Online CRBSI treatment purchases are also expected to provide patients with a degree of privacy and secrecy that can be significant to them. Without the potential difficulty or embarrassment of addressing delicate medical situations in person, they are projected to receive the essential drugs covertly. These aforementioned advantages of online pharmacies are estimated to bolster their demand worldwide.

Competitive Landscape

Drug manufacturers continuously focus on developing drug molecules that can target multiple indications. Several cutting-edge innovations are underway that can drastically reduce healthcare costs and the length of stay. Several prominent companies in the catheter-related bloodstream infection (CRBSI) treatment market are adopting strategies such as mergers & acquisitions, new product launches, patent generation, research activities, and collaborations.

For instance,

  • In September 2023, in a double-blind, phase 3 LOCK IT-100 trial, researchers at the University of California assigned 398 patients to receive heparin only infused into central venous catheters after dialysis sessions and 397 patients to receive taurolidine (13.5 mg/mL) with heparin (1000 units/mL). It was found that taurolidine/heparin lock solutions can reduce the risk of catheter-related bloodstream infections (CRBSIs).
  • In August 2023, the clinical trial for Mino-Lok reached an important milestone, according to Citius Pharmaceuticals, Inc. It is an antibiotic lock solution to save catheters in patients with catheter-related bloodstream infections. The company mentioned that all 92 events necessary to finish the trial have been accomplished. Several patients are still receiving treatment, which could lead to more occurrences.
  • In July 2023, Teva Pharmaceuticals, Inc. and Alvotech announced their plans to enhance an ongoing strategic partnership focused on the advancement and introduction of multiple biosimilar candidates. In this partnership, Teva will additionally invest US$ 40 million by acquiring subordinated convertible bonds to be issued by Alvotech.

Scope of the CRBSI Treatment Market Report

Attribute Details
Estimated Catheter-related Bloodstream Infection (CRBSI) Treatment Market Size (2023) US$ 1,541.3 million
Projected Catheter-related Bloodstream Infection (CRBSI) Treatment Market Valuation (2033) US$ 2,668.6 million
Value-based Catheter-related Bloodstream Infection (CRBSI) Treatment Market CAGR (2023 to 2033) 5.6%
Forecast Period 2023 to 2033
Historical Data Available for 2018 to 2022
Market Analysis Value (US$ million)
Key Regions Covered in Catheter-related Bloodstream Infection (CRBSI) Treatment Market North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa
Key Countries Covered in Catheter-related Bloodstream Infection (CRBSI) Treatment Market United States, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, United Kingdom, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa.
Key Segments Covered in Catheter-related Bloodstream Infection (CRBSI) Treatment Market Drug Class, Route of Administration, Indication, Distribution Channel, and Region
Key Companies Profiled in Catheter-related Bloodstream Infection (CRBSI) Treatment Market
  • Aurobindo Pharma Limited
  • B. Braun Medical Inc.
  • Eli Lilly and Company
  • Fresenius SE & Co. KGaA
  • GSK plc
  • Merck & Co., Inc.
  • Mylan N.V. (Viatris)
  • Novartis
  • Pfizer Inc.
  • Sanofi AG
  • SteriMax Inc.
  • Teva Pharmaceutical Industries Ltd.

Catheter-related Bloodstream Infection (CRBSI) Treatment Market Segments

By Drug Class:

  • Cloxacillin
  • Ceftazidime
  • Cefazoline
  • Daptomycin
  • Vancomycin
  • Teicoplanin
  • Echinocandin
  • Others

By Route of Administration:

  • Oral
  • Injectable

By Indication:

  • Bacterial Infections
  • Fungal Infection
  • Viral and Parasitic Infections

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

How big is the catheter-related bloodstream infection (CRBSI) treatment market?

The market is set to reach US$ 2,668.6 million by 2033.

What is the future outlook for the CRBSI treatment market?

The CRBSI treatment market is expected to witness a 5.6% CAGR from 2023 to 2033.

What are the leading CRBSI treatment drugs?

The echinocandin segment will likely showcase a 6.8% CAGR in the forecast period.

What are the latest trends in CRBSI treatment?

The development of innovative catheter designs and infection-resistant technologies is the latest trend.

Who are the dominant CRBSI treatment solution providers?

Novartis, GSK plc, and Pfizer Inc. are the leading providers.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply-Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Development/Innovation Trends

4. Value-Added Insights

    4.1. Drug Adoption / Usage Analysis, by Region (2022)

    4.2. Disease Epidemiology, By Region

    4.3. Patient Journey and Treatment Pattern Analysis

    4.4. Regulations Landscape

        4.4.1. Legal Requirements and Frameworks in the United States

        4.4.2. Legal Requirements and Frameworks in Europe

        4.4.3. Legal Requirements and Frameworks in Japan

        4.4.4. Legal Requirements and Frameworks in China

        4.4.5. Legal Requirements and Frameworks in India

        4.4.6. Legal Requirements and Frameworks in Australia

    4.5. Pipeline Assessment

    4.6. PESTLE Analysis

    4.7. Porter’s Analysis

    4.8. Value Chain Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global Healthcare Expenditure Outlook

        5.1.2. Research & Development funding By Region

        5.1.3. Pharmaceutical Spending

        5.1.4. Global Hospital Acquired Infection Treatment Market (Parent Market Analysis)

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Prevalence of Healthcare-Associated Infections

        5.2.2. Technological Advancements

        5.2.3. Growing Aging Population

        5.2.4. Rising Incidence of Chronic Diseases

        5.2.5. Hospital-Acquired Infection Reduction Initiatives

        5.2.6. Increasing Healthcare Expenditure

        5.2.7. Antimicrobial Resistance

        5.2.8. Regulatory Landscape

        5.2.9. Public Awareness and Education

        5.2.10. Research and Development

        5.2.11. Market Competition and Innovation

        5.2.12. New Drug Launches

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ million) Analysis 2018 to 2022 and Forecast, 2023 to 2033

    6.1. Historical Market Value (US$ million) Analysis, 2018 to 2022

    6.2. Current and Future Market Value (US$ million) Projections, 2023 to 2033

        6.2.1. Y-o-Y Growth Trend Analysis

        6.2.2. Absolute $ Opportunity Analysis

    6.3. Revenue Opportunity Analysis

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ million) By Drug Class, 2018 to 2022

    7.3. Current and Future Market Size (US$ million) and Forecast By Drug Class, 2023 to 2033

        7.3.1. Cloxacillin

        7.3.2. Ceftazidime

        7.3.3. Cefazoline

        7.3.4. Daptomycin

        7.3.5. Vancomycin

        7.3.6. Teicoplanin

        7.3.7. Echinocandin

        7.3.8. Others

    7.4. Market Attractiveness Analysis By Drug Class

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ million) By Route of Administration, 2018 to 2022

    8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Route of Administration, 2023 to 2033

        8.3.1. Oral

        8.3.2. Injectable

    8.4. Market Attractiveness Analysis By Route of Administration

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ million) By Indication, 2018 to 2022

    9.3. Current and Future Market Size (US$ million) Analysis and Forecast By Indication, 2023 to 2033

        9.3.1. Bacterial Infections

        9.3.2. Fungal Infection

        9.3.3. Viral and Parasitic Infections

    9.4. Market Attractiveness Analysis By Indication

10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ million) By Distribution Channel, 2018 to 2022

    10.3. Current and Future Market Size (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Drug Store

        10.3.4. Online Pharmacies

    10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ million) Trend Analysis by Region, 2018 to 2022

    11.3. Current and Future Market Size (US$ million) and Forecast by Region, 2023 to 2033

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. South Asia

        11.3.5. East Asia

        11.3.6. Oceania

        11.3.7. Middle East & Africa

    11.4. Market Attractiveness Analysis by Region

12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    12.1. Introduction

    12.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022

    12.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2023 to 2033

        12.3.1. By Country

            12.3.1.1. United States

            12.3.1.2. Canada

        12.3.2. By Drug Class

        12.3.3. By Route of Administration

        12.3.4. By Indication

        12.3.5. By Distribution Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Drug Class

        12.4.3. By Route of Administration

        12.4.4. By Indication

        12.4.5. By Distribution Channel

    12.5. Market Trends

    12.6. Drivers & Restraints Impact Analysis

    12.7. Country-Wise Analysis

        12.7.1. United States Market Analysis

            12.7.1.1. Introduction

            12.7.1.2. Market Analysis and Forecast by Market Taxonomy

                12.7.1.2.1. By Drug Class

                12.7.1.2.2. By Route of Administration

                12.7.1.2.3. By Indication

                12.7.1.2.4. By Distribution Channel

        12.7.2. Canada Market Analysis

            12.7.2.1. Introduction

            12.7.2.2. Market Analysis and Forecast by Market Taxonomy

                12.7.2.2.1. By Drug Class

                12.7.2.2.2. By Route of Administration

                12.7.2.2.3. By Indication

                12.7.2.2.4. By Distribution Channel

13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    13.1. Introduction

    13.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022

    13.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2023 to 2033

        13.3.1. By Country

            13.3.1.1. Brazil

            13.3.1.2. Mexico

            13.3.1.3. Argentina

            13.3.1.4. Peru

            13.3.1.5. Chile

            13.3.1.6. Columbia

            13.3.1.7. Rest of Latin America

        13.3.2. By Drug Class

        13.3.3. By Route of Administration

        13.3.4. By Indication

        13.3.5. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug Class

        13.4.3. By Route of Administration

        13.4.4. By Indication

        13.4.5. By Distribution Channel

    13.5. Market Trends

    13.6. Drivers & Restraints Impact Analysis

    13.7. Country-Wise Analysis

        13.7.1. Brazil Market Analysis

            13.7.1.1. Introduction

            13.7.1.2. Market Analysis and Forecast by Market Taxonomy

                13.7.1.2.1. By Drug Class

                13.7.1.2.2. By Route of Administration

                13.7.1.2.3. By Indication

                13.7.1.2.4. By Distribution Channel

        13.7.2. Mexico Market Analysis

            13.7.2.1. Introduction

            13.7.2.2. Market Analysis and Forecast by Market Taxonomy

                13.7.2.2.1. By Drug Class

                13.7.2.2.2. By Route of Administration

                13.7.2.2.3. By Indication

                13.7.2.2.4. By Distribution Channel

        13.7.3. Argentina Market Analysis

            13.7.3.1. Introduction

            13.7.3.2. Market Analysis and Forecast by Market Taxonomy

        13.7.4. By Drug Class

        13.7.5. By Route of Administration

        13.7.6. By Indication

        13.7.7. By Distribution Channel

        13.7.8. Peru Market Analysis

            13.7.8.1. Introduction

            13.7.8.2. Market Analysis and Forecast by Market Taxonomy

                13.7.8.2.1. By Drug Class

                13.7.8.2.2. By Route of Administration

                13.7.8.2.3. By Indication

                13.7.8.2.4. By Distribution Channel

        13.7.9. Chile Market Analysis

            13.7.9.1. Introduction

            13.7.9.2. Market Analysis and Forecast by Market Taxonomy

                13.7.9.2.1. By Drug Class

                13.7.9.2.2. By Route of Administration

                13.7.9.2.3. By Indication

                13.7.9.2.4. By Distribution Channel

        13.7.10. Columbia Market Analysis

            13.7.10.1. Introduction

            13.7.10.2. Market Analysis and Forecast by Market Taxonomy

                13.7.10.2.1. By Drug Class

                13.7.10.2.2. By Route of Administration

                13.7.10.2.3. By Indication

                13.7.10.2.4. By Distribution Channel

14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    14.1. Introduction

    14.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022

    14.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2023 to 2033

        14.3.1. By Country

            14.3.1.1. Germany

            14.3.1.2. France

            14.3.1.3. Spain

            14.3.1.4. Italy

            14.3.1.5. BENELUX

            14.3.1.6. Nordic Countries

            14.3.1.7. United Kingdom

            14.3.1.8. Rest of Europe

        14.3.2. By Drug Class

        14.3.3. By Route of Administration

        14.3.4. By Indication

        14.3.5. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug Class

        14.4.3. By Route of Administration

        14.4.4. By Indication

        14.4.5. By Distribution Channel

    14.5. Market Trends

    14.6. Drivers & Restraints Impact Analysis

    14.7. Country-Wise Analysis

        14.7.1. Germany Market Analysis

            14.7.1.1. Introduction

            14.7.1.2. Market Analysis and Forecast by Market Taxonomy

                14.7.1.2.1. By Drug Class

                14.7.1.2.2. By Route of Administration

                14.7.1.2.3. By Indication

                14.7.1.2.4. By Distribution Channel

        14.7.2. France Market Analysis

            14.7.2.1. Introduction

            14.7.2.2. Market Analysis and Forecast by Market Taxonomy

                14.7.2.2.1. By Drug Class

                14.7.2.2.2. By Route of Administration

                14.7.2.2.3. By Indication

                14.7.2.2.4. By Distribution Channel

        14.7.3. Spain Market Analysis

            14.7.3.1. Introduction

            14.7.3.2. Market Analysis and Forecast by Market Taxonomy

                14.7.3.2.1. By Drug Class

                14.7.3.2.2. By Route of Administration

                14.7.3.2.3. By Indication

                14.7.3.2.4. By Distribution Channel

        14.7.4. Italy Republic Market Analysis

            14.7.4.1. Introduction

            14.7.4.2. Market Analysis and Forecast by Market Taxonomy

                14.7.4.2.1. By Drug Class

                14.7.4.2.2. By Route of Administration

                14.7.4.2.3. By Indication

                14.7.4.2.4. By Distribution Channel

        14.7.5. BENELUX Republic Market Analysis

            14.7.5.1. Introduction

            14.7.5.2. Market Analysis and Forecast by Market Taxonomy

                14.7.5.2.1. By Drug Class

                14.7.5.2.2. By Route of Administration

                14.7.5.2.3. By Indication

                14.7.5.2.4. By Distribution Channel

        14.7.6. Nordic Countries Market Analysis

            14.7.6.1. Introduction

            14.7.6.2. Market Analysis and Forecast by Market Taxonomy

                14.7.6.2.1. By Drug Class

                14.7.6.2.2. By Route of Administration

                14.7.6.2.3. By Indication

                14.7.6.2.4. By Distribution Channel

        14.7.7. United Kingdom Market Analysis

            14.7.7.1. Introduction

            14.7.7.2. Market Analysis and Forecast by Market Taxonomy

                14.7.7.2.1. By Drug Class

                14.7.7.2.2. By Route of Administration

                14.7.7.2.3. By Indication

                14.7.7.2.4. By Distribution Channel

15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    15.1. Introduction

    15.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022

    15.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2023 to 2033

        15.3.1. By Country

            15.3.1.1. India

            15.3.1.2. Indonesia

            15.3.1.3. Philippines

            15.3.1.4. Thailand

            15.3.1.5. Malaysia

            15.3.1.6. Vietnam

            15.3.1.7. Rest of South Asia

        15.3.2. By Drug Class

        15.3.3. By Route of Administration

        15.3.4. By Indication

        15.3.5. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug Class

        15.4.3. By Route of Administration

        15.4.4. By Indication

        15.4.5. By Distribution Channel

    15.5. Market Trends

    15.6. Drivers & Restraints Impact Analysis

    15.7. Country-Wise Analysis

        15.7.1. India Market Analysis

            15.7.1.1. Introduction

            15.7.1.2. Market Analysis and Forecast by Market Taxonomy

                15.7.1.2.1. By Drug Class

                15.7.1.2.2. By Route of Administration

                15.7.1.2.3. By Indication

                15.7.1.2.4. By Distribution Channel

        15.7.2. Indonesia Market Analysis

            15.7.2.1. Introduction

            15.7.2.2. Market Analysis and Forecast by Market Taxonomy

                15.7.2.2.1. By Drug Class

                15.7.2.2.2. By Route of Administration

                15.7.2.2.3. By Indication

                15.7.2.2.4. By Distribution Channel

        15.7.3. Philippines Market Analysis

            15.7.3.1. Introduction

            15.7.3.2. Market Analysis and Forecast by Market Taxonomy

                15.7.3.2.1. By Drug Class

                15.7.3.2.2. By Route of Administration

                15.7.3.2.3. By Indication

                15.7.3.2.4. By Distribution Channel

        15.7.4. Thailand Market Analysis

            15.7.4.1. Introduction

            15.7.4.2. Market Analysis and Forecast by Market Taxonomy

                15.7.4.2.1. By Drug Class

                15.7.4.2.2. By Route of Administration

                15.7.4.2.3. By Indication

                15.7.4.2.4. By Distribution Channel

        15.7.5. Malaysia Market Analysis

            15.7.5.1. Introduction

            15.7.5.2. Market Analysis and Forecast by Market Taxonomy

                15.7.5.2.1. By Drug Class

                15.7.5.2.2. By Route of Administration

                15.7.5.2.3. By Indication

                15.7.5.2.4. By Distribution Channel

        15.7.6. Vietnam Market Analysis

            15.7.6.1. Introduction

            15.7.6.2. Market Analysis and Forecast by Market Taxonomy

                15.7.6.2.1. By Drug Class

                15.7.6.2.2. By Route of Administration

                15.7.6.2.3. By Indication

                15.7.6.2.4. By Distribution Channel

16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    16.1. Introduction

    16.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022

    16.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2023 to 2033

        16.3.1. By Country

            16.3.1.1. China

            16.3.1.2. Japan

            16.3.1.3. South Korea

        16.3.2. By Drug Class

        16.3.3. By Route of Administration

        16.3.4. By Indication

        16.3.5. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug Class

        16.4.3. By Route of Administration

        16.4.4. By Indication

        16.4.5. By Distribution Channel

    16.5. Market Trends

    16.6. Drivers & Restraints Impact Analysis

    16.7. Country-Wise Analysis

        16.7.1. China Market Analysis

            16.7.1.1. Introduction

            16.7.1.2. Market Analysis and Forecast by Market Taxonomy

                16.7.1.2.1. By Drug Class

                16.7.1.2.2. By Route of Administration

                16.7.1.2.3. By Indication

                16.7.1.2.4. By Distribution Channel

        16.7.2. Japan Market Analysis

            16.7.2.1. Introduction

            16.7.2.2. Market Analysis and Forecast by Market Taxonomy

                16.7.2.2.1. By Drug Class

                16.7.2.2.2. By Route of Administration

                16.7.2.2.3. By Indication

                16.7.2.2.4. By Distribution Channel

        16.7.3. South Korea Market Analysis

            16.7.3.1. Introduction

            16.7.3.2. Market Analysis and Forecast by Market Taxonomy

                16.7.3.2.1. By Drug Class

                16.7.3.2.2. By Route of Administration

                16.7.3.2.3. By Indication

                16.7.3.2.4. By Distribution Channel

17. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    17.1. Introduction

    17.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022

    17.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2023 to 2033

        17.3.1. By Country

            17.3.1.1. Australia

            17.3.1.2. New Zealand

        17.3.2. By Drug Class

        17.3.3. By Route of Administration

        17.3.4. By Indication

        17.3.5. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug Class

        17.4.3. By Route of Administration

        17.4.4. By Indication

        17.4.5. By Distribution Channel

    17.5. Market Trends

    17.6. Drivers & Restraints Impact Analysis

    17.7. Country-Wise Analysis

        17.7.1. Australia Market Analysis

            17.7.1.1. Introduction

            17.7.1.2. Market Analysis and Forecast by Market Taxonomy

                17.7.1.2.1. By Drug Class

                17.7.1.2.2. By Route of Administration

                17.7.1.2.3. By Indication

                17.7.1.2.4. By Distribution Channel

        17.7.2. New Zealand Market Analysis

            17.7.2.1. Introduction

            17.7.2.2. Market Analysis and Forecast by Market Taxonomy

                17.7.2.2.1. By Drug Class

                17.7.2.2.2. By Route of Administration

                17.7.2.2.3. By Indication

                17.7.2.2.4. By Distribution Channel

18. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    18.1. Introduction

    18.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022

    18.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2023 to 2033

        18.3.1. By Country

            18.3.1.1. GCC Countries

            18.3.1.2. Türkiye

            18.3.1.3. Northern Africa

            18.3.1.4. South Africa

            18.3.1.5. Israel

            18.3.1.6. Rest of Middle East & Africa

        18.3.2. By Drug Class

        18.3.3. By Route of Administration

        18.3.4. By Indication

        18.3.5. By Distribution Channel

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Drug Class

        18.4.3. By Route of Administration

        18.4.4. By Indication

        18.4.5. By Distribution Channel

    18.5. Market Trends

    18.6. Drivers & Restraints Impact Analysis

    18.7. Country-Wise Analysis

        18.7.1. GCC Countries Market Analysis

            18.7.1.1. Introduction

            18.7.1.2. Market Analysis and Forecast by Market Taxonomy

                18.7.1.2.1. By Drug Class

                18.7.1.2.2. By Route of Administration

                18.7.1.2.3. By Indication

                18.7.1.2.4. By Distribution Channel

        18.7.2. Türkiye Market Analysis

            18.7.2.1. Introduction

            18.7.2.2. Market Analysis and Forecast by Market Taxonomy

                18.7.2.2.1. By Drug Class

                18.7.2.2.2. By Route of Administration

                18.7.2.2.3. By Indication

                18.7.2.2.4. By Distribution Channel

        18.7.3. Northern Africa Market Analysis

            18.7.3.1. Introduction

            18.7.3.2. Market Analysis and Forecast by Market Taxonomy

                18.7.3.2.1. By Drug Class

                18.7.3.2.2. By Route of Administration

                18.7.3.2.3. By Indication

                18.7.3.2.4. By Distribution Channel

        18.7.4. South Africa Market Analysis

            18.7.4.1. Introduction

            18.7.4.2. Market Analysis and Forecast by Market Taxonomy

                18.7.4.2.1. By Drug Class

                18.7.4.2.2. By Route of Administration

                18.7.4.2.3. By Indication

                18.7.4.2.4. By Distribution Channel

        18.7.5. Israel Market Analysis

            18.7.5.1. Introduction

            18.7.5.2. Market Analysis and Forecast by Market Taxonomy

                18.7.5.2.1. By Drug Class

                18.7.5.2.2. By Route of Administration

                18.7.5.2.3. By Indication

                18.7.5.2.4. By Distribution Channel

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies

    19.2. Market Share Analysis of Top Players (%)

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Competition Benchmarking

    20.3. Branding and Promotional Strategies, By Key Manufactures

    20.4. Key Development Analysis

    20.5. Competition Deep Dive

        20.5.1. Baxter International

            20.5.1.1. Overview

            20.5.1.2. Product Portfolio

            20.5.1.3. Key Financials

            20.5.1.4. SWOT Analysis

            20.5.1.5. Key Developments

            20.5.1.6. Sales Footprint

            20.5.1.7. Strategy Overview

                20.5.1.7.1. Marketing Strategy

                20.5.1.7.2. Product Strategy

                20.5.1.7.3. Channel Strategy

        20.5.2. Aurobindo Pharma Limited

            20.5.2.1. Overview

            20.5.2.2. Product Portfolio

            20.5.2.3. Key Financials

            20.5.2.4. SWOT Analysis

            20.5.2.5. Key Developments

            20.5.2.6. Sales Footprint

            20.5.2.7. Strategy Overview

                20.5.2.7.1. Marketing Strategy

                20.5.2.7.2. Product Strategy

                20.5.2.7.3. Channel Strategy

        20.5.3. B. Braun Medical Inc.

            20.5.3.1. Overview

            20.5.3.2. Product Portfolio

            20.5.3.3. Key Financials

            20.5.3.4. SWOT Analysis

            20.5.3.5. Key Developments

            20.5.3.6. Sales Footprint

            20.5.3.7. Strategy Overview

                20.5.3.7.1. Marketing Strategy

                20.5.3.7.2. Product Strategy

                20.5.3.7.3. Channel Strategy

        20.5.4. Eli Lilly and Company

            20.5.4.1. Overview

            20.5.4.2. Product Portfolio

            20.5.4.3. Key Financials

            20.5.4.4. SWOT Analysis

            20.5.4.5. Key Developments

            20.5.4.6. Sales Footprint

            20.5.4.7. Strategy Overview

                20.5.4.7.1. Marketing Strategy

                20.5.4.7.2. Product Strategy

                20.5.4.7.3. Channel Strategy

        20.5.5. Fresenius SE & Co. KGaA

            20.5.5.1. Overview

            20.5.5.2. Product Portfolio

            20.5.5.3. Key Financials

            20.5.5.4. SWOT Analysis

            20.5.5.5. Key Developments

            20.5.5.6. Sales Footprint

            20.5.5.7. Strategy Overview

                20.5.5.7.1. Marketing Strategy

                20.5.5.7.2. Product Strategy

                20.5.5.7.3. Channel Strategy

        20.5.6. GSK plc

            20.5.6.1. Overview

            20.5.6.2. Product Portfolio

            20.5.6.3. Key Financials

            20.5.6.4. SWOT Analysis

            20.5.6.5. Key Developments

            20.5.6.6. Sales Footprint

            20.5.6.7. Strategy Overview

                20.5.6.7.1. Marketing Strategy

                20.5.6.7.2. Product Strategy

                20.5.6.7.3. Channel Strategy

        20.5.7. Merck & Co., Inc.

            20.5.7.1. Overview

            20.5.7.2. Product Portfolio

            20.5.7.3. Key Financials

            20.5.7.4. SWOT Analysis

            20.5.7.5. Key Developments

            20.5.7.6. Sales Footprint

            20.5.7.7. Strategy Overview

                20.5.7.7.1. Marketing Strategy

                20.5.7.7.2. Product Strategy

                20.5.7.7.3. Channel Strategy

        20.5.8. Mylan N.V. (Viatris)

            20.5.8.1. Overview

            20.5.8.2. Product Portfolio

            20.5.8.3. Key Financials

            20.5.8.4. SWOT Analysis

            20.5.8.5. Key Developments

            20.5.8.6. Sales Footprint

            20.5.8.7. Strategy Overview

                20.5.8.7.1. Marketing Strategy

                20.5.8.7.2. Product Strategy

                20.5.8.7.3. Channel Strategy

        20.5.9. Novartis

            20.5.9.1. Overview

            20.5.9.2. Product Portfolio

            20.5.9.3. Key Financials

            20.5.9.4. SWOT Analysis

            20.5.9.5. Key Developments

            20.5.9.6. Sales Footprint

            20.5.9.7. Strategy Overview

                20.5.9.7.1. Marketing Strategy

                20.5.9.7.2. Product Strategy

                20.5.9.7.3. Channel Strategy

        20.5.10. Pfizer Inc.

            20.5.10.1. Overview

            20.5.10.2. Product Portfolio

            20.5.10.3. Key Financials

            20.5.10.4. SWOT Analysis

            20.5.10.5. Key Developments

            20.5.10.6. Sales Footprint

            20.5.10.7. Strategy Overview

                20.5.10.7.1. Marketing Strategy

                20.5.10.7.2. Product Strategy

                20.5.10.7.3. Channel Strategy

        20.5.11. Sanofi AG

            20.5.11.1. Overview

            20.5.11.2. Product Portfolio

            20.5.11.3. Key Financials

            20.5.11.4. SWOT Analysis

            20.5.11.5. Key Developments

            20.5.11.6. Sales Footprint

            20.5.11.7. Strategy Overview

                20.5.11.7.1. Marketing Strategy

                20.5.11.7.2. Product Strategy

                20.5.11.7.3. Channel Strategy

        20.5.12. SteriMax Inc.

            20.5.12.1. Overview

            20.5.12.2. Product Portfolio

            20.5.12.3. Key Financials

            20.5.12.4. SWOT Analysis

            20.5.12.5. Key Developments

            20.5.12.6. Sales Footprint

            20.5.12.7. Strategy Overview

                20.5.12.7.1. Marketing Strategy

                20.5.12.7.2. Product Strategy

                20.5.12.7.3. Channel Strategy

        20.5.13. Teva Pharmaceutical Industries Ltd.

            20.5.13.1. Overview

            20.5.13.2. Product Portfolio

            20.5.13.3. Key Financials

            20.5.13.4. SWOT Analysis

            20.5.13.5. Key Developments

            20.5.13.6. Sales Footprint

            20.5.13.7. Strategy Overview

                20.5.13.7.1. Marketing Strategy

                20.5.13.7.2. Product Strategy

                20.5.13.7.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 01: Global Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 02: Global Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

Table 03: Global Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

Table 04: Global Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 05: Global Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

Table 06: North America Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 07: North America Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 08: North America Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

Table 09: North America Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

Table 10: North America Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 11: Latin America Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 12: Latin America Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 13: Latin America Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

Table 14: Latin America Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

Table 15: Latin America Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 16: Europe Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 17: Europe Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 18: Europe Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

Table 19: Europe Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

Table 20: Europe Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 21: South Asia Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 22: South Asia Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 23: South Asia Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

Table 24: South Asia Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

Table 25: South Asia Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 26: East Asia Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 27: East Asia Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 28: East Asia Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

Table 29: East Asia Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

Table 30: East Asia Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 31: Oceania Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 32: Oceania Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 33: Oceania Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

Table 34: Oceania Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

Table 35: Oceania Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 36: Middle East & Africa Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 37: Middle East & Africa Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 38: Middle East & Africa Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

Table 39: Middle East & Africa Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

Table 40: Middle East & Africa Market Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 01: Global Market Value Share By Drug Class (2022 A)

Figure 02: Global Market Value Share By Route of Administration (2022 A)

Figure 03: Global Market Value Share By Indication (2022 A)

Figure 04: Global Market Value Share By Distribution Channel (2022 A)

Figure 05: Global Market Value Share By Region (2022 A)

Figure 06: Global Market Value Analysis (US$ million), 2018 to 2022

Figure 07: Global Market Value Forecast (US$ million), 2023 to 2033

Figure 08: Global Market Absolute Market Absolute $ Opportunity, 2023 to 2033

Figure 09: Global Market Share Analysis (%), By Drug Class, 2023(E) & 2033(F)

Figure 10: Global Market Y-o-Y Analysis (%), By Drug Class, 2023 to 2033

Figure 11: Global Market Attractiveness Analysis By Drug Class, 2023 to 2033

Figure 12: Global Market Share Analysis (%), By Route of Administration, 2023 (E) and 2033 (F)

Figure 13: Global Market Y-o-Y Analysis (%), By Route of Administration, 2023 to 2033

Figure 14: Global Market Attractiveness Analysis By Route of Administration, 2023 to 2033

Figure 15: Global Market Share Analysis (%), By Indication, 2023 (E) and 2033 (F)

Figure 16: Global Market Y-o-Y Analysis (%), By Indication, 2023 to 2033

Figure 17: Global Market Attractiveness Analysis By Indication, 2023 to 2033

Figure 18: Global Market Share Analysis (%), By Distribution Channel, 2023 (E) and 2033 (F)

Figure 19: Global Market Y-o-Y Analysis (%), By Distribution Channel, 2023 to 2033

Figure 20: Global Market Attractiveness Analysis By Distribution Channel, 2023 to 2033

Figure 21: Global Market Share Analysis (%), By Region, 2023(E) & 2033(F)

Figure 22: Global Market Y-o-Y Analysis (%), By Region, 2023 to 2033

Figure 23: Global Market Attractiveness Analysis By Region, 2023 to 2033

Figure 24: North America Market Value Share By Drug Class (2022 A)

Figure 25: North America Market Value Share By Route of Administration (2022 A)

Figure 26: North America Market Value Share By Indication (2022 A)

Figure 27: North America Market Value Share By Distribution Channel (2022 A)

Figure 28: North America Market Value Share By Country (2022 A)

Figure 29: North America Market Value Analysis (US$ million), 2018 to 2022

Figure 30: North America Market Value Forecast (US$ million), 2023 to 2033

Figure 31: North America Market Attractiveness Analysis By Drug Class, 2023 to 2033

Figure 32: North America Market Attractiveness Analysis By Route of Administration, 2023 to 2033

Figure 33: North America Market Attractiveness Analysis By Indication, 2023 to 2033

Figure 34: North America Market Attractiveness Analysis By Distribution Channel, 2023 to 2033

Figure 35: North America Market Attractiveness Analysis By Country, 2023 to 2033

Figure 36: Latin America Market Value Share By Drug Class (2022 A)

Figure 37: Latin America Market Value Share By Route of Administration (2022 A)

Figure 38: Latin America Market Value Share By Indication (2022 A)

Figure 39: Latin America Market Value Share By Distribution Channel (2022 A)

Figure 40: Latin America Market Value Share By Country (2022 A)

Figure 41: Latin America Market Value Analysis (US$ million), 2018 to 2022

Figure 42: Latin America Market Value Forecast (US$ million), 2023 to 2033

Figure 43: Latin America Market Attractiveness Analysis By Drug Class, 2023 to 2033

Figure 44: Latin America Market Attractiveness Analysis By Route of Administration, 2023 to 2033

Figure 45: Latin America Market Attractiveness Analysis By Indication, 2023 to 2033

Figure 46: Latin America Market Attractiveness Analysis By Distribution Channel, 2023 to 2033

Figure 47: Latin America Market Attractiveness Analysis By Country, 2023 to 2033

Figure 48: Europe Market Value Share By Drug Class (2022 A)

Figure 49: Europe Market Value Share By Route of Administration (2022 A)

Figure 50: Europe Market Value Share By Indication (2022 A)

Figure 51: Europe Market Value Share By Distribution Channel (2022 A)

Figure 52: Europe Market Value Share By Country (2022 A)

Figure 53: Europe Market Value Analysis (US$ million), 2018 to 2022

Figure 54: Europe Market Value Forecast (US$ million), 2023 to 2033

Figure 55: Europe Market Attractiveness Analysis By Drug Class, 2023 to 2033

Figure 56: Europe Market Attractiveness Analysis By Route of Administration, 2023 to 2033

Figure 57: Europe Market Attractiveness Analysis By Indication, 2023 to 2033

Figure 58: Europe Market Attractiveness Analysis By Distribution Channel, 2023 to 2033

Figure 59: Europe Market Attractiveness Analysis By Country, 2023 to 2033

Figure 60: South Asia Market Value Share By Drug Class (2022 A)

Figure 61: South Asia Market Value Share By Route of Administration (2022 A)

Figure 62: South Asia Market Value Share By Indication (2022 A)

Figure 63: South Asia Market Value Share By Distribution Channel (2022 A)

Figure 64: South Asia Market Value Share By Country (2022 A)

Figure 65: South Asia Market Value Analysis (US$ million), 2018 to 2022

Figure 66: South Asia Market Value Forecast (US$ million), 2023 to 2033

Figure 67: South Asia Market Attractiveness Analysis By Drug Class, 2023 to 2033

Figure 68: South Asia Market Attractiveness Analysis By Route of Administration, 2023 to 2033

Figure 69: South Asia Market Attractiveness Analysis By Indication, 2023 to 2033

Figure 70: South Asia Market Attractiveness Analysis By Distribution Channel, 2023 to 2033

Figure 71: South Asia Market Attractiveness Analysis By Country, 2023 to 2033

Figure 72: East Asia Market Value Share By Drug Class (2022 A)

Figure 73: East Asia Market Value Share By Route of Administration (2022 A)

Figure 74: East Asia Market Value Share By Indication (2022 A)

Figure 75: East Asia Market Value Share By Distribution Channel (2022 A)

Figure 76: East Asia Market Value Share By Country (2022 A)

Figure 77: East Asia Market Value Analysis (US$ million), 2018 to 2022

Figure 78: East Asia Market Value Forecast (US$ million), 2023 to 2033

Figure 79: East Asia Market Attractiveness Analysis By Drug Class, 2023 to 2033

Figure 80: East Asia Market Attractiveness Analysis By Route of Administration, 2023 to 2033

Figure 81: East Asia Market Attractiveness Analysis By Indication, 2023 to 2033

Figure 82: East Asia Market Attractiveness Analysis By Distribution Channel, 2023 to 2033

Figure 83: East Asia Market Attractiveness Analysis By Country, 2023 to 2033

Figure 84: Oceania Market Value Share By Drug Class (2022 A)

Figure 85: Oceania Market Value Share By Route of Administration (2022 A)

Figure 86: Oceania Market Value Share By Indication (2022 A)

Figure 87: Oceania Market Value Share By Distribution Channel (2022 A)

Figure 88: Oceania Market Value Share By Country (2022 A)

Figure 89: Oceania Market Value Analysis (US$ million), 2018 to 2022

Figure 90: Oceania Market Value Forecast (US$ million), 2023 to 2033

Figure 91: Oceania Market Attractiveness Analysis By Drug Class, 2023 to 2033

Figure 92: Oceania Market Attractiveness Analysis By Route of Administration, 2023 to 2033

Figure 93: Oceania Market Attractiveness Analysis By Indication, 2023 to 2033

Figure 94: Oceania Market Attractiveness Analysis By Distribution Channel, 2023 to 2033

Figure 95: Oceania Market Attractiveness Analysis By Country, 2023 to 2033

Figure 96: Middle East & Africa Market Value Share By Drug Class (2022 A)

Figure 97: Middle East & Africa Market Value Share By Route of Administration (2022 A)

Figure 98: Middle East & Africa Market Value Share By Indication (2022 A)

Figure 99: Middle East & Africa Market Value Share By Distribution Channel (2022 A)

Figure 100: Middle East & Africa Market Value Share By Country (2022 A)

Figure 101: Middle East & Africa Market Value Analysis (US$ million), 2018 to 2022

Figure 102: Middle East & Africa Market Value Forecast (US$ million), 2023 to 2033

Figure 103: Middle East & Africa Market Attractiveness Analysis By Drug Class, 2023 to 2033

Figure 104: Middle East & Africa Market Attractiveness Analysis By Route of Administration, 2023 to 2033

Figure 105: Middle East & Africa Market Attractiveness Analysis By Indication, 2023 to 2033

Figure 106: Middle East & Africa Market Attractiveness Analysis By Distribution Channel, 2023 to 2033

Figure 107: Middle East & Africa Market Attractiveness Analysis By Country, 2023 to 2033

Recommendations

Healthcare

Dyspnea Treatment Market

Published : March 2023

Healthcare

Treatment-Resistant Hypertension Management Market

Published : March 2023

Healthcare

Venous Ulcer Treatment Market

Published : February 2023

Healthcare

Treatment-Resistant Depression Treatment Market

Published : December 2022

Explore Healthcare Insights

View Reports